291 related articles for article (PubMed ID: 35251028)
1. Antagonistic Antibody Targeting TNFR2 Inhibits Regulatory T Cell Function to Promote Anti-Tumor Activity.
Chen Y; Jia M; Wang S; Xu S; He N
Front Immunol; 2022; 13():835690. PubMed ID: 35251028
[TBL] [Abstract][Full Text] [Related]
2. MiR-125b-5p modulates the function of regulatory T cells in tumor microenvironment by targeting TNFR2.
Jiang M; Yang Y; Niu L; Li P; Chen Y; Liao P; Wang Y; Zheng J; Chen F; He H; Li H; Chen X
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36319063
[TBL] [Abstract][Full Text] [Related]
3. TNFR2 antagonistic antibody induces the death of tumor infiltrating CD4
He T; Chen Y; Yang D; Islam MS; Chou CK; Liu J; Faustman DL; Oppenheim JJ; Chen X
Cell Oncol (Dordr); 2023 Feb; 46(1):167-177. PubMed ID: 36369606
[TBL] [Abstract][Full Text] [Related]
4. The effects of TNF-α/TNFR2 in regulatory T cells on the microenvironment and progression of gastric cancer.
Qu Y; Wang X; Bai S; Niu L; Zhao G; Yao Y; Li B; Li H
Int J Cancer; 2022 Apr; 150(8):1373-1391. PubMed ID: 34766338
[TBL] [Abstract][Full Text] [Related]
5. The Significance of Tumor Necrosis Factor Receptor Type II in CD8
Ye LL; Wei XS; Zhang M; Niu YR; Zhou Q
Front Immunol; 2018; 9():583. PubMed ID: 29623079
[TBL] [Abstract][Full Text] [Related]
6. TNFR2 blockade alone or in combination with PD-1 blockade shows therapeutic efficacy in murine cancer models.
Case K; Tran L; Yang M; Zheng H; Kuhtreiber WM; Faustman DL
J Leukoc Biol; 2020 Jun; 107(6):981-991. PubMed ID: 32449229
[TBL] [Abstract][Full Text] [Related]
7. Scutellarin enhances anti-tumor immune responses by reducing TNFR2-expressing CD4
Chen S; Li R; Chen Y; Chou CK; Zhang Z; Yang Y; Liao P; Wang Q; Chen X
Biomed Pharmacother; 2022 Jul; 151():113187. PubMed ID: 35676787
[TBL] [Abstract][Full Text] [Related]
8. Increased Regulatory T Cells in Peripheral Blood of Acute Myeloid Leukemia Patients Rely on Tumor Necrosis Factor (TNF)-α-TNF Receptor-2 Pathway.
Wang M; Zhang C; Tian T; Zhang T; Wang R; Han F; Zhong C; Hua M; Ma D
Front Immunol; 2018; 9():1274. PubMed ID: 29922294
[TBL] [Abstract][Full Text] [Related]
9. Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs.
Torrey H; Butterworth J; Mera T; Okubo Y; Wang L; Baum D; Defusco A; Plager S; Warden S; Huang D; Vanamee E; Foster R; Faustman DL
Sci Signal; 2017 Jan; 10(462):. PubMed ID: 28096513
[TBL] [Abstract][Full Text] [Related]
10. Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors.
Zhang X; Lao M; Xu J; Duan Y; Yang H; Li M; Ying H; He L; Sun K; Guo C; Chen W; Jiang H; Zhang X; Bai X; Liang T
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35260434
[TBL] [Abstract][Full Text] [Related]
11. A TNFR2 antibody by countering immunosuppression cooperates with HMGN1 and R848 immune stimulants to inhibit murine colon cancer.
Jiang M; Liu J; Yang D; Tross D; Li P; Chen F; Alam MM; Faustman DL; Oppenheim JJ; Chen X
Int Immunopharmacol; 2021 Dec; 101(Pt A):108345. PubMed ID: 34794079
[TBL] [Abstract][Full Text] [Related]
12. Cutting edge: expression of TNFR2 defines a maximally suppressive subset of mouse CD4+CD25+FoxP3+ T regulatory cells: applicability to tumor-infiltrating T regulatory cells.
Chen X; Subleski JJ; Kopf H; Howard OM; Männel DN; Oppenheim JJ
J Immunol; 2008 May; 180(10):6467-71. PubMed ID: 18453563
[TBL] [Abstract][Full Text] [Related]
13. TNFR2-expressing CD4
He J; Li R; Chen Y; Hu Y; Chen X
Prog Mol Biol Transl Sci; 2019; 164():101-117. PubMed ID: 31383403
[TBL] [Abstract][Full Text] [Related]
14. Expression of TNFR2 by regulatory T cells in peripheral blood is correlated with clinical pathology of lung cancer patients.
Yan F; Du R; Wei F; Zhao H; Yu J; Wang C; Zhan Z; Ding T; Ren X; Chen X; Li H
Cancer Immunol Immunother; 2015 Nov; 64(11):1475-85. PubMed ID: 26280204
[TBL] [Abstract][Full Text] [Related]
15. An Autocrine TNFα-Tumor Necrosis Factor Receptor 2 Loop Promotes Epigenetic Effects Inducing Human Treg Stability
Urbano PCM; Koenen HJPM; Joosten I; He X
Front Immunol; 2018; 9():573. PubMed ID: 29619032
[TBL] [Abstract][Full Text] [Related]
16. Control of GVHD by regulatory T cells depends on TNF produced by T cells and TNFR2 expressed by regulatory T cells.
Leclerc M; Naserian S; Pilon C; Thiolat A; Martin GH; Pouchy C; Dominique C; Belkacemi Y; Charlotte F; Maury S; Salomon BL; Cohen JL
Blood; 2016 Sep; 128(12):1651-9. PubMed ID: 27506541
[TBL] [Abstract][Full Text] [Related]
17. Ansofaxine hydrochloride inhibits tumor growth and enhances Anti-TNFR2 in murine colon cancer model.
Jing Q; Wan Q; Nie Y; Luo J; Zhang X; Zhu L; Gui H; Li L; Wang C; Chen S; Wang M; Yuan H; Lv H; Pan R; Jing Q; Nie Y
Front Pharmacol; 2023; 14():1286061. PubMed ID: 38161697
[No Abstract] [Full Text] [Related]
18. Regulatory T cells express Tumor Necrosis Factor Receptor 2 with the highest intensity among CD4
Ghods A; Mehdipour F; Shariat M; Talei AR; Ghaderi A
Mol Immunol; 2021 Sep; 137():52-56. PubMed ID: 34214829
[TBL] [Abstract][Full Text] [Related]
19. TNFR2: A Novel Target for Cancer Immunotherapy.
Vanamee ÉS; Faustman DL
Trends Mol Med; 2017 Nov; 23(11):1037-1046. PubMed ID: 29032004
[TBL] [Abstract][Full Text] [Related]
20. Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy.
Williams GS; Mistry B; Guillard S; Ulrichsen JC; Sandercock AM; Wang J; González-Muñoz A; Parmentier J; Black C; Soden J; Freeth J; Jovanović J; Leyland R; Al-Lamki RS; Leishman AJ; Rust SJ; Stewart R; Jermutus L; Bradley JR; Bedian V; Valge-Archer V; Minter R; Wilkinson RW
Oncotarget; 2016 Oct; 7(42):68278-68291. PubMed ID: 27626702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
